Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy
Top Cited Papers
- 29 September 2006
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 103 (3) , 303-311
- https://doi.org/10.1007/s10549-006-9380-z
Abstract
Purpose To explore the relationship of regional cerebral blood flow and metabolism with cognitive function and past exposure to chemotherapy for breast cancer. Patients and methods Subjects treated for breast cancer with adjuvant chemotherapy remotely (5–10 years previously) were studied with neuropsychologic testing and positron emission tomography (PET), and were compared with control subjects who had never received chemotherapy. [O-15] water PET scans was acquired during performance of control and memory-related tasks to evaluate cognition-related cerebral blood flow, and [F-18] fluorodeoxyglucose (FDG) PET scans were acquired to evaluate resting cerebral metabolism. PET scans were analyzed by statistical parametric mapping and region of interest methods of analysis. Results During performance of a short-term recall task, modulation of cerebral blood flow in specific regions of frontal cortex and cerebellum was significantly altered in chemotherapy-treated subjects. Cerebral activation in chemotherapy-treated subjects differed most significantly from untreated subjects in inferior frontal gyrus, and resting metabolism in this area correlated with performance on a short-term memory task previously found to be particularly impaired in chemotherapy-treated subjects. In examining drug-class specific effects, metabolism of the basal ganglia was significantly decreased in tamoxifen + chemotherapy-treated patients compared with chemotherapy-only breast cancer subjects or with subjects who had not received chemotherapy, while chemotherapy alone was not associated with decreased basal ganglia activity relative to untreated subjects. Conclusion Specific alterations in activity of frontal cortex, cerebellum, and basal ganglia in breast cancer survivors were documented by functional neuroimaging 5–10 years after completion of chemotherapy.Keywords
This publication has 63 references indexed in Scilit:
- Breast Cancer Treatment and Cognitive Functioning: Current Status and Future Challenges in AssessmentBreast Cancer Research and Treatment, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinomaCancer, 2004
- Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot studyPsycho‐Oncology, 2003
- Nulliparity and Late Menopause Are Associated With Decreased Cognitive DeclineThe Journal of Neuropsychiatry and Clinical Neurosciences, 2003
- Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and LymphomaJournal of Clinical Oncology, 2002
- The immune system and memory consolidation: a role for the cytokine IL-1βNeuroscience & Biobehavioral Reviews, 2001
- Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancerPsycho‐Oncology, 1995
- Estrogen receptors in human nontarget tissues: biological and clinical implicationsEndocrine Reviews, 1995
- Predicting premorbid IQ: A revision of the national adult reading testThe Clinical Neuropsychologist, 1989